Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)

Market Cap	40.54B
Revenue (ttm)	5.23B
Net Income (ttm)	1.27B
Shares Out	1.98B
EPS (ttm)	0.64
PE Ratio	32.13
Forward PE	29.48
Dividend	0.13 (0.61%)
Ex-Dividend Date	n/a

Volume	4,998,262
Open	20.93
Previous Close	20.93
Day's Range	20.77 - 20.97
52-Week Range	20.17 - 27.60
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 29, 2025

About Beijing Tiantan Biological Products

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 4,858
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2023, Beijing Tiantan Biological Products's revenue was 5.18 billion, an increase of 21.57% compared to the previous year's 4.26 billion. Earnings were 1.11 billion, an increase of 25.99%.